Published: October 9, 2026
Nutritional Outlook examines how the sleep supplement category is moving beyond sedation toward botanicals that address stress, mood and the physical factors behind poor rest.
The article cites a global sleep supplement market valued at $8.55 billion in 2025, with botanical extracts gaining ground among formulators and consumers.
Ashwagandha and bacopa are discussed for their effects on cortisol, and saffron for its dual role in mood and sleep. Maypro’s SaffonX is cited for an eight-week, 30 mg trial showing better sleep quality, lower perceived stress and reduced cortisol.
Two other Maypro ingredients appear: Venetron, a 50 mg Apocynum venetum leaf extract linked to longer non-REM sleep, and ETAS, an asparagus stem extract that activates HSP70 and reduced nighttime waking in a 14-day study.
Lauren Clardy, Maypro’s senior director of scientific affairs, contributes commentary throughout.
